Melanoma (Skin)
Conditions
Keywords
stage IV melanoma, recurrent melanoma
Brief summary
RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.
Interventions
BIOLOGICALdendritic cell-MART-1 peptide vaccine
Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
Sponsors
National Institutes of Health (NIH)
Jonsson Comprehensive Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* This study is confined to adults over the age of 18 with histologically proven malignant melanoma. * MART-1, as assessed by either RT-PCR or by immunohistochemistry. * Subjects must be typed for HLA-A\*0201 for the phase I part of the study, and HLA-A\*0201 and/or DR\*04 for the phase II part. * Stage with unresectable measurable melanoma (stage IV or stage III unresectable). Patients previously treated with any form of therapy (including chemotherapy, radiation therapy, immunotherapy or surgery) for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous the previous treatment was completed \> 30 days prior to first vaccine. * Both male and female patients may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment. * Karnofsky Performance Status greater than or equal to 70 percent, or ECOG greater than 2. * No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease. * No previous evidence of opportunistic infection. * A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy. * Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry: * Hemoglobin \> 9.0 g/dl. * Platelets \> 100,000/mm3. * WBC \> 3,000/mm3. * Absolute Neutrophil Count (ANC) \> 1,000/mm3. * Ability to give informed consent.
Exclusion criteria
Patients who meet any one of the following criteria will be excluded from study entry: * Lactating females: Females of child-bearing potential (pre-menopausal) must have a negative serum beta-HCG pregnancy test (within Day -7 to Day 0). * Acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy. Acute therapy must have been completed within 14 days prior to study treatment. * HIV-infected patients, due to concerns in the ability to stimulate an effective immune response. * Acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk. * Patients with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents ). * Patients with organ allografts. * Uncontrolled CNS metastasis. Patients with CNS metastasis will be eligible if they have received CNS irradiation to control local tumor growth. * Previous clinical evidence of an autoimmune disease. * Concomitant Medication and Treatment All allowed medications or treatments should be kept to a minimum and recorded. All questions regarding concomitant medications should be referred to the study chair or investigator. Medications and Treatments Not Allowed * Corticosteroids * Chemotherapy * Cyclosporin A.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal dose | 7 months |
Secondary
| Measure | Time frame |
|---|---|
| Safety of administering MART-1 adenovirus transduced dendritic cells | 7 months |
| Immunological response (peptide-specific T cell generation, skin test immunohistology) | 7 months |
| Clinical response (disease improvement or disease progression) | 7 months |
Countries
United States
Outcome results
None listed